Saul Priceman, Ph.D.
Research performed at: City of Hope Comprehensive Cancer Center
Specialty/Research Area: Cancer Immunotherapy, T-Cells, Tumor Immunology
Career Summary: Dr. Priceman is an Assistant Research Professor in the T Cell Immunotherapy Program at City of Hope and a trained tumor immunologist with expertise in T cell biology and cancer immunotherapy. He is developing Chimeric antigen receptor (CAR)-based T cell immunotherapy primarily for solid cancers, with a strong focus on metastatic disease in breast, prostate, and pancreatic cancer. Dr. Priceman received his BS in Microbiology at the University of California, Santa Barbara; and his PhD in Molecular and Medical Pharmacology at the University of California, Los Angeles.
Dr. Priceman is a Principal Investigator on a Prostate Cancer Foundation Young Investigator award, a co-Principal Investigator on a Prostate Cancer Foundation Challenge Award, and a Principal Investigator on a National Comprehensive Cancer Network Young Investigator award, leading the development of HER2-specific CAR T therapy for metastatic breast cancers, and working with his team optimizing new CAR T cell therapies for various other solid cancers. Dr. Priceman is deeply committed to rapidly advancing potentially paradigm-shifting immunotherapy on behalf of patients with cancer, in part because of personal experiences with family and friends who have struggled with the disease. His overarching goal is to develop a range of effective immunotherapies for solid cancers, based on the powerful CAR T cell platform, with the knowledge that any single therapy will not likely provide durable responses in advanced disease.
Year STOP CANCER Award was received: 2017 DISRUPT | STOP CANCER SEED GRANT
Description of research performed: The overall goal of this proposal is to develop a breast cancer-specific HER2-CAR T cell to preferentially target over-expressed and/or amplified HER2 expressing tumors using preclinical models that faithfully recapitulate systemic metastases observed in breast cancer patients. These studies will ultimately lead to an IND submission for testing this therapy in clinical trials, with potential to significantly improve outcomes for patients battling this disease